

Nabihah Tayob

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/520681/publications.pdf>

Version: 2024-02-01

45
papers

2,362
citations

430874

18
h-index

265206

42
g-index

45
all docs

45
docs citations

45
times ranked

3611
citing authors

#	ARTICLE	IF	CITATIONS
1	The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 415-423.e4.	4.4	56
2	GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. <i>Hepatology</i> , 2022, 75, 541-549.	7.3	70
3	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.8	11
4	Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 201-210.	2.5	0
5	A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. <i>Statistics in Medicine</i> , 2022, 41, 2338-2353.	1.6	1
6	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	5.2	8
7	DETECT: Development of Technologies for Early HCC Detection. <i>Gastroenterology</i> , 2022, 163, 21-27.	1.3	4
8	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100974.	0.6	5
9	Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. <i>Cancer Biomarkers</i> , 2022, 33, 199-210.	1.7	0
10	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	5.2	18
11	Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1443-1450.e6.	4.4	13
12	Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 983-991.	7.0	29
13	Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 843-852.	2.5	7
14	Factors associated with late risks of breast cancer-specific mortality in the SEER registry. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 203-212.	2.5	11
15	Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1531-1539.	1.6	88
16	Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. <i>Gynecologic Oncology</i> , 2021, 161, 581-586.	1.4	5
17	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells. <i>JCO Precision Oncology</i> , 2021, 5, 896-903.	3.0	6
18	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	2.5	19

#	ARTICLE	IF	CITATIONS
19	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	1.3	91
20	A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 411-423.	2.5	3
21	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
22	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	5.2	17
23	A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. <i>Nature Communications</i> , 2021, 12, 5574.	12.8	32
24	Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. <i>Oncologist</i> , 2021, 26, 927-933.	3.7	5
25	Perceptions of patients with early stage breast cancer toward research biopsies. <i>Cancer</i> , 2021, 127, 1208-1219.	4.1	3
26	Regression analysis of recurrent event-free time from multiple follow-up windows. <i>Statistics in Medicine</i> , 2020, 39, 1-15.	1.6	1
27	Validation of the Hepatocellular Carcinoma Early Detection Screening (HES) Algorithm in a Cohort of Veterans With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1886-1893.e5.	4.4	36
28	Nonparametric group sequential methods for recurrent and terminal events from multiple follow-up windows. <i>Statistics in Medicine</i> , 2019, 38, 5657-5669.	1.6	2
29	Nonparametric Group Sequential Methods for Evaluating Survival Benefit from Multiple Short-Term Follow-up Windows. <i>Biometrics</i> , 2019, 75, 494-505.	1.4	1
30	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 1648-1655.	0.8	33
31	Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPD Gene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 265-267.	5.6	29
32	Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. <i>BMC Medical Research Methodology</i> , 2018, 18, 1.	3.1	390
33	A Bayesian Screening Approach for Hepatocellular Carcinoma Using Multiple Longitudinal Biomarkers. <i>Biometrics</i> , 2018, 74, 249-259.	1.4	16
34	Statistical consequences of a successful lung allocation system - recovering information and reducing bias in models for urgency. <i>Statistics in Medicine</i> , 2017, 36, 2435-2451.	1.6	4
35	Unbiased Estimation of Biomarker Panel Performance When Combining Training and Testing Data in a Group Sequential Design. <i>Biometrics</i> , 2016, 72, 888-896.	1.4	4
36	Nonparametric restricted mean analysis across multiple follow-up intervals. <i>Statistics and Probability Letters</i> , 2016, 109, 152-158.	0.7	2

#	ARTICLE	IF	CITATIONS
37	Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2016, 149, 491-498.	0.8	75
38	Improved Detection of Hepatocellular Carcinoma by Using a Longitudinal Alpha-Fetoprotein Screening Algorithm. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 469-475.e2.	4.4	67
39	Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events. <i>Biostatistics</i> , 2015, 16, 73-83.	1.5	7
40	Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1503-1508.	5.6	155
41	Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. <i>Lancet Respiratory Medicine</i> , 2014, 2, 548-556.	10.7	353
42	Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function. <i>Chest</i> , 2014, 145, 579-585.	0.8	95
43	Spread of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South Africa. <i>PLoS ONE</i> , 2011, 6, e17513.	2.5	29
44	Risk of Pancreatic Cancer in Families With Lynch Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 1790.	7.4	434
45	Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 0, , .	7.1	51